|
Prestin as a Biomarker for Hearing Loss in Cisplatin Therapy
|
|
20-230-2
|
|
Prestin as a Biomarker for Hearing Loss in Cisplatin Therapy
|
|
Dr. Kourosh Parham
|
|
Cisplatin is a widely used and effective chemotherapeutic agent but well-known for also causing hearing loss or ototoxicity. However, there is currently no available blood-based biomarker test to evaluate the onset of ototoxicity in patients undergoing cisplatin. Diagnostic blood tests are easy to obtain and non-invasive and can provide critical information for treatment, intervention, and even prevention of downstream pathology. Several animal studies have shown outer hair cell electromotility protein prestin to be a promising biomarker for ototoxicity, however it has yet to be applied in human studies. Our hypothesis is that prestin may present as a measurable and specific serological biomarker for early detection of ototoxicity secondary to cisplatin chemotherapy. Our specific aim is to determine a temporal relationship between prestin levels and cisplatin treatment.
|
Cancer - General
|
|
Ear, Nose and Throat
|
|
Taste/Smell/Hearing
|
|
|
Check with study contact
|
|
Ruby Feng. Telephone: Not Available. Email: rfeng@uchc.edu
|
|
Enrolling/recruiting. For current recruitment status, please check with study contact.
|
|
|